NASDAQ:SYRS

Syros Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy SYRS

*Your capital is at risk

$0.0002

+0 (+0%)

At Close: Jun 02, 2026

Syros Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 28.21. In total, the insiders bought 1.07M and sold 1.21M SYRS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	28.21
● Buy	1.07M shares
● Sell	1.21M shares
74% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Jun 01, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 28.21. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 31, 2024 Buy	Common Stock M-Exempt	Stephens Kristin Chief Development Officer	Officer	17 000 Value: $42.8K
Oct 31, 2024 Sell	Common Stock F-InKind	Stephens Kristin Chief Development Officer	Officer	6 104 Value: $12.8K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Stephens Kristin Chief Development Officer	Officer	17 000 Value: $42.8K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Stephens Kristin Chief Development Officer	Officer	17 000 Value: $42.8K
Oct 31, 2024 Sell	Common Stock F-InKind	Stephens Kristin Chief Development Officer	Officer	6 104 Value: $12.8K
Oct 31, 2024 Buy	Common Stock M-Exempt	Stephens Kristin Chief Development Officer	Officer	17 000 Value: $42.8K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Chee Conley President & CEO	CEO / President	17 000 Value: $42.8K
Oct 31, 2024 Sell	Common Stock F-InKind	Chee Conley President & CEO	CEO / President	8 707 Value: $18.2K
Oct 31, 2024 Buy	Common Stock M-Exempt	Chee Conley President & CEO	CEO / President	17 000 Value: $42.8K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Haas Jason Chief Financial Officer	C-Suite Officer	18 875 Value: $47.6K
Oct 31, 2024 Sell	Common Stock F-InKind	Haas Jason Chief Financial Officer	C-Suite Officer	5 624 Value: $11.8K
Oct 31, 2024 Buy	Common Stock M-Exempt	Haas Jason Chief Financial Officer	C-Suite Officer	18 875 Value: $47.6K
Oct 31, 2024 Buy	Common Stock M-Exempt	Roth David Chief Medical Officer	Officer	18 875 Value: $47.6K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Simonian Nancy A Director	Director	40 125 Value: $101.1K
Oct 31, 2024 Buy	Common Stock M-Exempt	Simonian Nancy A Director	Director	40 125 Value: $101.1K
Oct 31, 2024 Buy	Restricted Stock Units M-Exempt	Roth David Chief Medical Officer	Officer	18 875 Value: $47.6K
Oct 31, 2024 Sell	Common Stock F-InKind	Roth David Chief Medical Officer	Officer	6 776 Value: $14.2K
Sep 30, 2024 Buy	Common Stock M-Exempt	Quirk Gerald E Chief Legal & Compliance Offic	Officer	10 000 Value: $21.5K
Sep 30, 2024 Sell	Common Stock F-InKind	Quirk Gerald E Chief Legal & Compliance Offic	Officer	3 100 Value: $7K
Sep 30, 2024 Buy	Restricted Stock Units M-Exempt	Quirk Gerald E Chief Legal & Compliance Offic	Officer	10 000 Value: $21.5K
Sep 30, 2024 Buy	Restricted Stock Units M-Exempt	Quirk Gerald E Chief Legal & Compliance Offic	Officer	10 000 Value: $21.5K
Sep 30, 2024 Sell	Common Stock F-InKind	Quirk Gerald E Chief Legal & Compliance Offic	Officer	3 100 Value: $7K
Sep 30, 2024 Buy	Common Stock M-Exempt	Quirk Gerald E Chief Legal & Compliance Offic	Officer	10 000 Value: $21.5K
Sep 16, 2024 Buy	Common Stock M-Exempt	Akkaraju Srinivas Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Restricted Stock Units M-Exempt	Akkaraju Srinivas Director	Director	2 667 Value: $5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SYROS PHARMACEUTICALS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...

Read Full Profile Here